Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2024

Genmab — Maj 2024

Planlagt Fastgjort Låst Flyttet Genmab
540 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #98

    🙂 Godmorgen @solsen 1600. Problemet med analytiker kursmål er at vi for det meste ikke ved hvad de har indregnet i deres mål med mindre man har adgang til hele analysen som der generelt kan være meget forskel på fra 1 side til 30 sider. Hvor meget renten vægter o.s.v. Nogle analytikere ved en del om Genmab og andre meget lidt.

    1 Reply Last reply
    0
    • V Offline
      V Offline
      Vougeot
      wrote on sidst redigeret af
      #99

      Træerne vokser desværre ikke ind i himlen

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Riis7
        wrote on sidst redigeret af
        #100

        dead cat bounce

        1 Reply Last reply
        0
        • V Offline
          V Offline
          Vitus
          wrote on sidst redigeret af
          #101

          Ikke overrasket….

          1 Reply Last reply
          0
          • royalR Offline
            royalR Offline
            royal
            wrote on sidst redigeret af
            #102

            Gevinst hjemtagning. Lille omsætning. Den retter sig nok senere idag.

            1 Reply Last reply
            0
            • V Offline
              V Offline
              Vitus
              wrote on sidst redigeret af
              #103

              De der tager gevinst i Genmab har forhåbentlig tagetbden

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #104

                Rome lung cancer summit
                https://twitter.com/StephenVLiu/status/1787396191535112279/photo/2

                1 Reply Last reply
                0
                • V Offline
                  V Offline
                  Vitus
                  wrote on sidst redigeret af
                  #105

                  Tager den for længe siden….

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #106

                    What are they saying EL ?

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #107

                      he mentions acasunlimab / GEN1046
                      but most of the other drugs he mentions on that slide have discontinued development; showing what a difficult area it is to succeed.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #108

                        here tisotumab mentioned as NSCLC drug, doubt it , but who knows
                        https://twitter.com/StephenVLiu/status/1787419518131654815/photo/2

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          GeorgeBest
                          wrote on sidst redigeret af
                          #109

                          Hvis I har en LinkedIn profil, vil jeg anbefale at følge Claus Johansen. Han har mange gode indlæg om sundhedsaktier, deriblandt Genmab

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #110

                            https://investors.biontech.de/static-files/c8ca4858-2a59-45ab-bc43-6b1df6e3e784 biontech Q1 '24 presentation

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #111

                              5 fællesprogrammer/-stoffer med Genmab. Imponerende og se deres optag af pts i forsøg. Det er nu Biontech ruller deres forsøg ud,

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                lahn1
                                wrote on sidst redigeret af
                                #112

                                Thx EL do we expect NSCLC data this side of summer ?

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #113

                                  I doubt that, we will get cervical & head and neck cancer at ASCO though. head and neck should be the next area to go into; they said they will speak with regulators about the next steps for that

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #114

                                    i would be surprised to see them go further with NSCLC, there is so much competition there... but i don't mind being surprised 😉 I would have expected ovarian cancer to be more logical

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #115

                                      If they se a chance they will persue it. Huge market.

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #116

                                        Transactions in Connection with Share Buy-back Program https://www.proinvestor.com/investornyt/1155522/transactions-in-connection-with-share-buy-back-program

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #117

                                          BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/05/06/biontech-se-bntx-q1-2024-earnings-call-transcript/

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper